Global Bladder Cancer Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

Transitional Cell Carcinoma, Invasive Bladder Cancer, Superficial Bladder Cancer, Adenocarcinomax, and Other Rare Types.

By Treatment;

Chemotherapy, Radiation Therapy, Immunotherapy, Radical Cystectomy, and Others

By Diagnosis;

Urine Lab Tests - Urinalysis, Urine Cytology, Urine Culture and Urine Tumor Marker Test, Cystoscopy, Biopsy, Imaging Test, and Other.

By End-Use;

Hospital, Clinic, and Cancer Care Centers.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn166561544 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Bladder Cancer Market (USD Million), 2021 - 2031

In the year 2024, the Global Bladder Cancer Market was valued at USD 4,012.61 million. The size of this market is expected to increase to USD 5,280.33 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.0%.

Bladder cancer is characterized by abnormal cell growth within the bladder. Currently, standard treatments such as chemotherapy, surgery, and radiation therapy are employed to manage the disease. However, ongoing research aims to develop bladder cancer drugs as alternatives to these methods, aiming to mitigate the side effects associated with conventional treatments.

Bladder cancer manifests in various forms, including urothelial carcinoma, adenocarcinoma, squamous cell bladder cancer, among others. According to the American Society of Clinical Oncology (ASCO), urothelial carcinoma constitutes nearly 90% of all bladder cancer cases. This predominant type underscores the importance of targeted therapies and advancements in treatment modalities for effectively combating bladder cancer.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Treatment
    3. Market Snapshot, By Diagnosis
    4. Market Snapshot, By End-Use
    5. Market Snapshot, By Region
  4. Global Bladder Cancer Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Bladder Cancer Cases
        2. Technological Advancements
        3. Increasing Healthcare Awareness
      2. Restraints
        1. High Cost of Treatment
        2. Stringent Regulatory Processes
      3. Opportunities
        1. Focus on Minimally Invasive Procedures
        2. Personalized Medicine
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Bladder Cancer Market, By Type, 2021 - 2031 (USD Million)
      1. Transitional Cell Carcinoma
      2. Invasive Bladder Cancer
      3. Superficial Bladder Cancer
      4. Adenocarcinomax
      5. Other Rare Types
    2. Global Bladder Cancer Market, By Treatment, 2021 - 2031 (USD Million)
      1. Chemotherapy
      2. Radiation Therapy
      3. Immunotherapy
      4. Radical Cystectomy
      5. Others
    3. Global Bladder Cancer Market, By Diagnosis, 2021 - 2031 (USD Million)
      1. Urine Lab Tests
      2. Urinalysis
      3. Urine Cytology
      4. Urine Culture
      5. Urine Tumor Marker Test
      6. Cystoscopy
      7. Biopsy
      8. Imaging Test
      9. Other
    4. Global Bladder Cancer Market, By End-Use, 2021 - 2031 (USD Million)
      1. Hospital
      2. Clinic
      3. Cancer Care Centers
    5. Global Bladder Cancer Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AstraZeneca Plc
      2. Bristol-Myers Squibb Company
      3. Celgene Corporation
      4. Eli Lilly and Company (U.S.)
      5. F. Hoffmann-La Roche AG (Switzerland)
      6. GlaxoSmithKline Plc
      7. Novartis International AG (Switzerland), Pfizer Inc.
  7. Analyst Views
  8. Future Outlook of the Market